Pharma BD Deal Intelligence
Celgene acquired Receptos for $7.2B for ozanimod.
Celgene spends $7.2 billion on Receptos purchase, driven by the potential of ozanimod for ulcerative colitis and multiple sclerosis as the company diversifies…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
Celgene acquired Receptos for $7.2B for ozanimod.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Celgene Corporation / Receptos Inc. (this deal) | 2015 | $7.2B | 63 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2015 | $2.0B | 85 |
| Celgene Corporation / Agios Pharmaceuticals Inc. | 2010 | $130M | 83 |
| Celgene Corporation / Bristol-Myers Squibb Company | 2018 | $9.0B | 68 |
| Celgene Corporation / Abraxis BioScience Inc. | 2010 | $2.9B | 65 |
| Celgene Corporation / Impact Biomedicines | 2018 | $7.0B | 54 |
| Celgene Corporation / Gloucester Pharmaceuticals, Inc. | 2009 | $640M | 40 |
← Browse all deals · How we score deals
More: 2015 deals · Celgene Corporation deals · Gastroenterology deals